Ethic Inc. Moderna, Inc. Transaction History

Ethic Inc.

$3.97 Billion
Q3 2024

A detailed history of Ethic Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Ethic Inc. holds 21,176 shares of MRNA stock, worth $780,335. This represents 0.04% of its overall portfolio holdings.

Number of Shares

21,176

Previous 24,612 13.96%

Holding current value

$780,335

Previous $2.92 Million 51.57%

% of portfolio

0.04%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$63.64 - $125.14 $218,667 - $429,981	-3,436 Reduced 13.96%	21,176 $1.42 Million
Q2 2024 Aug 13, 2024	BUY	$101.21 - $166.61 $347,757 - $572,471	3,436 Added 16.23%	24,612 $2.92 Million
Q1 2024 May 13, 2024	BUY	$85.37 - $115.44 $971,766 - $1.31 Million	11,383 Added 116.24%	21,176 $2.26 Million
Q4 2023 Feb 14, 2024	BUY	$69.51 - $104.43 $29,124 - $43,756	419 Added 4.47%	9,793 $973,000
Q3 2023 Nov 14, 2023	SELL	$96.41 - $126.61 $2,024 - $2,658	-21 Reduced 0.22%	9,374 $968,000
Q2 2023 Aug 14, 2023	SELL	$118.5 - $160.53 $307,507 - $416,575	-2,595 Reduced 21.64%	9,395 $1.14 Million
Q1 2023 May 12, 2023	BUY	$135.66 - $197.02 $613,725 - $891,318	4,524 Added 60.59%	11,990 $1.84 Million
Q4 2022 Feb 14, 2023	BUY	$118.38 - $210.04 $340,697 - $604,495	2,878 Added 62.73%	7,466 $1.34 Million
Q3 2022 Nov 14, 2022	BUY	$118.07 - $194.18 $185,487 - $305,056	1,571 Added 52.07%	4,588 $543,000
Q2 2022 Aug 10, 2022	BUY	$117.13 - $176.59 $139,384 - $210,142	1,190 Added 65.13%	3,017 $431,000
Q1 2022 May 16, 2022	SELL	$126.46 - $235.05 $277,200 - $515,229	-2,192 Reduced 54.54%	1,827 $315,000
Q4 2021 Feb 14, 2022	BUY	$225.82 - $368.51 $907,570 - $1.48 Million	4,019 New	4,019 $1.02 Million

Others Institutions Holding MRNA

# of Institutions

954

Shares Held

241M

Call Options Held

10.6M

Put Options Held

18.7M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ethic Inc. with notifications on news.

Account